PMID- 28096940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240325
IS  - 1911-6470 (Print)
IS  - 1911-6470 (Linking)
VI  - 10
IP  - 11-12Suppl7
DP  - 2016 Nov-Dec
TI  - The next 10 years: Challenges for the future and overcoming resistance to 
      targeted therapies for renal cell carcinoma.
PG  - S256-S258
LID - 10.5489/cuaj.4294 [doi]
AB  - The introduction of targeted therapies over the past 10 years revolutionized the 
      treatment of metastatic renal cell carcinoma (mRCC). The next 10 years hold 
      promise for even greater expansion of the therapeutic armamentarium for mRCC. A 
      number of recently completed and ongoing trials have explored the use of 
      antivascular endothelial growth factor receptor (VEGFR) tyrosine kinase 
      inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the 
      adjuvant setting, the use of predictive biomarkers to guide personalized 
      medicine, as well as new systemic treatments and combination therapies for mRCC.
FAU - Heng, Daniel Y C
AU  - Heng DY
AD  - Tom Baker Cancer Centre, Calgary, and Department of Medicine, University of 
      Calgary, Calgary, AB, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC5215305
EDAT- 2017/01/18 06:00
MHDA- 2017/01/18 06:01
PMCR- 2016/11/01
CRDT- 2017/01/19 06:00
PHST- 2017/01/19 06:00 [entrez]
PHST- 2017/01/18 06:00 [pubmed]
PHST- 2017/01/18 06:01 [medline]
PHST- 2016/11/01 00:00 [pmc-release]
AID - cuaj-11-12-s256 [pii]
AID - 10.5489/cuaj.4294 [doi]
PST - ppublish
SO  - Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S256-S258. doi: 10.5489/cuaj.4294.